Genelux (GNLX) PE Ratio: History & Chart

Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.

The P/E ratio is N/A as of 2026-10-06T17:36:41.027Z.

Stored calculation inputs

Calculation as of: 2026-10-06T17:36:41.027Z.

Quote observation: 2026-10-06T17:35:09.000Z. Amounts in USD. The price header may show a later quote.

Quote price: 2.555
Unrounded diluted TTM EPS · period ending 2026-06-30: -0.89

FMP input reference: 9a1dfb6c252c1cf241c11dff63bdf10e98668db23039cc4017602387c5996572

Forward PE Ratio|PEG Ratio|P/B Ratio|EPS|All Metrics

GNLX PE Ratio Metrics

PE RATIO

N/A

GNLX Competitors' PE Ratio

GNLX

Genelux Corporation

Current

Market Cap

$114.57M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MXCT

MaxCyte, Inc.

vs GNLX

Market Cap

$113.53M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CRBU

Caribou Biosciences, Inc.

vs GNLX

Market Cap

$115.05M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AARD

Aardvark Therapeutics, Inc. Common Stock

vs GNLX

Market Cap

$112.70M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IMDX

Insight Molecular Diagnostics Inc.

vs GNLX

Market Cap

$112.53M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

COYA

Coya Therapeutics, Inc.

vs GNLX

Market Cap

$115.64M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LUCD

Lucid Diagnostics Inc.

vs GNLX

Market Cap

$112.19M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

FHTX

Foghorn Therapeutics Inc.

vs GNLX

Market Cap

$111.84M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LENZ

LENZ Therapeutics, Inc.

vs GNLX

Market Cap

$116.80M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

APYX

Apyx Medical Corporation

vs GNLX

Market Cap

$110.39M

PE Ratio

N/A

TTM Avg

3.95

3Y Avg

3.95

5Y Avg

3.95

NAME	MARKET CAP	PE RATIO	TTM	3Y	5Y
Genelux Corporation (GNLX)	$114.57M	N/A	N/A	N/A	N/A
MaxCyte, Inc. (MXCT)vs ›	$113.53M	N/A	N/A	N/A	N/A
Caribou Biosciences, Inc. (CRBU)vs ›	$115.05M	N/A	N/A	N/A	N/A
Aardvark Therapeutics, Inc. Common Stock (AARD)vs ›	$112.70M	N/A	N/A	N/A	N/A
Insight Molecular Diagnostics Inc. (IMDX)vs ›	$112.53M	N/A	N/A	N/A	N/A
Coya Therapeutics, Inc. (COYA)vs ›	$115.64M	N/A	N/A	N/A	N/A
Lucid Diagnostics Inc. (LUCD)vs ›	$112.19M	N/A	N/A	N/A	N/A
Foghorn Therapeutics Inc. (FHTX)vs ›	$111.84M	N/A	N/A	N/A	N/A
LENZ Therapeutics, Inc. (LENZ)vs ›	$116.80M	N/A	N/A	N/A	N/A
Apyx Medical Corporation (APYX)vs ›	$110.39M	N/A	3.95	3.95	3.95

P/E Comparison

Trailing P/E

N/A

Forward P/E

N/A

Forward P/E Calculation

View All Analyst Estimates

Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.

Calculation:

Current Price

$2.56

÷

Forward EPS (Est.)

$-0.81

=

Forward P/E

N/A

Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.

PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

See the Lowest P/E Ratio Stocks ranking →

PE Ratio: N/A

GNLX PE Ratio Metrics

GNLX Competitors' PE Ratio

P/E Comparison

Forward P/E Calculation

PE Ratio Formula & Definition

Related Metrics